Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT05010525
Other study ID # ATG-016-ST-001
Secondary ID
Status Terminated
Phase Phase 1/Phase 2
First received
Last updated
Start date September 1, 2021
Est. completion date November 14, 2022

Study information

Verified date July 2022
Source Antengene Corporation
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is A Phase Ib/II Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of ATG 016 Monotherapy in Patients with Advanced Solid Tumors


Description:

This is A Phase Ib/II Open-label, Multi-centre, Dose Finding Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of ATG 016 Monotherapy in Patients with Advanced Solid Tumors


Recruitment information / eligibility

Status Terminated
Enrollment 8
Est. completion date November 14, 2022
Est. primary completion date November 14, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Understand and voluntarily sign informed Consent (ICF) prior to any assessment/procedure related to study. 2. Age =18 years at ICF signature. 3. Estimated life expectancy of minimum of 12 weeks. 4. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 at ICF signature. 5. Subjects must have at least one measurable lesion as defined by RECIST version 1.1. 6. Females of childbearing potential must agree to use effective contraception from the time ICF signature until 180 days after the last dose. Females of childbearing potential include those who are premenopausal and those who are 2 years postmenopausal. Blood pregnancy tests must be negative for female of childbearing potential must have a negative serum pregnancy test at Screening. Inclusion Criteria Only for Phase Ib study (Dose Escalation and Expansion phase) 1. Histological or cytological confirmation of a solid tumor, and have progressed despite standard therapy(ies), or are intolerant to standard therapy(ies), or have no standard therapy(ies) exists. Inclusion Criteria Only for Phase II 1. Penile squamous cell carcinomas confirmed by cytology or histology cannot be excised by radical surgery, or postoperative recurrence or metastasis which is not suitable for platinum chemotherapy or platinum resistance or platinum failure. 2. Nasopharyngeal carcinoma Exclusion Criteria: Subjects with any of the following conditions will not be enrolled in this study. 1. Central nervous system (CNS) metastases and involvement. 2. A history of bone marrow or organ transplantation. 3. Prior ATG-016 administration or other XPO1 inhibitor treatment. 4. Known to be allergic to the active or inactive ingredients of ATG-016 or drugs with similar chemical structure, or the subject is hypersensitive. 5. Prior therapy with any investigational drugs or systemic anticancer treatment (eg, a period of 5 'half-lives' of drugs, whichever is longer) within 28 days at the time of ICF signature. 6. Received extensive radiation within 28 days at the time of ICF signature or expect to undergo radical radiotherapy during the study period. 7. Received major surgery within 28 days at the time of ICF signature or expect to proceed a major surgical treatment during the study period. 8. Any toxicities unresolved to Grade 1 or baseline from prior anti-tumor therapy (According to NCI-CTCAE 5.0) with the exception of alopecia, within 28 days at the time of ICF signature. 9. Any uncontrolled active infection requiring parenteral treatment of antibiotics, antivirals, or antifungals at the time of ICF signature or within one week of Cycle 1 Day 1 (C1D1). Active hepatitis B virus (HBV) infection (Hepatitis B surface antigen [HBsAg] positive) or active HCV infection (HCV-RNA positive at screening). 10. A history of HIV infection and/or acquired immunodeficiency syndrome. 11. Received immunosuppressive medication within 14 days at the time of ICF signature. 12. Cardiovascular diseases of clinical significance 13. Inadequate bone marrow reserve or organ function as demonstrated by any of the following laboratory values: 14. Have a history of another primary malignancy within 5 years prior to starting study treatment, with following exceptions: malignancy tumors treated by radical therapy and have not been recurred, such as carcinoma in situ of the cervix, basal cell carcinoma or squamous cell carcinoma of the skin, papillary thyroid carcinoma, etc. 15. Inability or unwillingness to comply with the requirement for oral drug administration, or presence of a gastrointestinal diseases or other clinical conditions that would compromise the absorption of study drug, eg, refractory nausea and vomiting, inability to swallow the formulated product, or previous significant bowel resection, etc. 16. Active or a history of bleeding within 6 months. 17. Received any live attenuated vaccination within 28 days at the signature of ICF. 18. Judgment by the investigator that the subject should not participate in the study by consideration of the complications or other conditions which might affect their adherence to the protocol. 19. Female subjects who are pregnant or lactating.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
ATG-016
48 patients enrolled, orally, each 3 week (21-day) a cycle

Locations

Country Name City State
China The First Affiliated Hospital of Bengbu Medical College Bengbu Bengbu Anhui
China West China Hospital, Sichuan University Chengdu Sichuan
China Chongqing Cancer Hospital Chongqing Chonqing
China The First Affiliated Hospital of Xiamen University Xiaomen Fujian

Sponsors (1)

Lead Sponsor Collaborator
Shanghai Antengene Corporation Limited

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary MTD in Phase I MTD will be evaluated using the NCI-CTCAE, Version 5.0 16 months
Primary RP2D in Phase I RP2D will be determined under the guidance of the SRC. 16 months
Primary AEs Toxicity will be graded according to the NCI CTCAE, Version 5.0. 25 months
Primary SAEs Toxicity will be graded according to the NCI CTCAE, Version 5.0. 25 months
Primary ORR in Phase II Based on 2006 IWG Response Criteria, evaluated by IRC: ORR (CR + PR + mCR) 25 months
Secondary Disease Control Rate (DCR) in Phase I/II DCR (CR + PR + mCR + HI + SD) 16 months
Secondary Duration of Response (DOR) in Phase I/II To evaluate duration of response 12 months
Secondary Overall Survival (OS) The estimates of Kaplan-Meier 12 months
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04972981 - A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-901 in Participants With Selected Advanced Solid Tumors Phase 1
Completed NCT05086822 - A Study of Irinotecan Hydrochloride Liposome in Advanced Solid Tumors Phase 1
Completed NCT03260322 - A Multiple-dose Study of ASP8374, an Immune Checkpoint Inhibitor, as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors Phase 1
Completed NCT02526017 - Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers Phase 1
Recruiting NCT06040541 - Study of RMC-9805 in Participants With KRASG12D-Mutant Solid Tumors Phase 1
Recruiting NCT05862831 - Clinical Study of PM1003 in Phase I/IIa Treatment of Advanced Malignant Solid Tumors Phase 1/Phase 2
Recruiting NCT03641794 - Indoleamine 2,3-Dioxygenase (IDO) Inhibitor in Healthy Volunteers Phase 1
Terminated NCT03665129 - IPH5401 (Anti-C5aR) in Combination With Durvalumab in Patients With Advanced Solid Tumors Phase 1
Not yet recruiting NCT06413680 - A First-In Human (FIH) Trial to Find Out if REGN10597 is Safe and How Well it Works for Adult Participants With Advanced Solid Organ Malignancies Phase 1/Phase 2
Recruiting NCT05914116 - A Study of DB-1311 in Advanced/Metastatic Solid Tumors Phase 1/Phase 2
Completed NCT01693562 - A Phase 1/2 Study to Evaluate MEDI4736 Phase 1/Phase 2
Recruiting NCT04387916 - A Study of KC1036 in Patients With Advanced Solid Tumors Phase 1
Completed NCT04095273 - Study to Test How Well Patients With Advanced Solid Tumors Respond to Treatment With the Elimusertib in Combination With Pembrolizumab, to Find the Optimal Dose for Patients, How the Drug is Tolerated and the Way the Body Absorbs, Distributes and Discharges the Drug Phase 1
Not yet recruiting NCT03692520 - Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of SCT200 in Patients With Advanced Solid Tumors Phase 1
Completed NCT02997176 - An Open-Label Pharmacokinetics and Safety Study of Talazoparib (MDV3800) Phase 1
Recruiting NCT04446260 - A Study of SHR-A1811 in Subjects With Advanced Malignant Solid Tumors Phase 1
Recruiting NCT06239155 - A Phase I/II Study of AST-3424 in Subjects With Advanced Solid Tumors Phase 1/Phase 2
Terminated NCT02253992 - An Investigational Immuno-therapy Study to Determine the Safety of Urelumab Given in Combination With Nivolumab in Solid Tumors and B-cell Non-Hodgkin's Lymphoma Phase 1/Phase 2
Recruiting NCT06076291 - An Open-label Study of SG1827 in Subjects With Advanced Solid Tumors Phase 1
Completed NCT03545971 - A Study of IBI310 for the Treatment of Patients With Advanced Solid Tumors. Phase 1